052 - BATTLING for the Top Anti-VEGF Eye Therapy
Happy Thanksgiving! In this video, I talk about all things related to eye diseases caused by...
21:44
Podcasts de pharma
In this episode, Heather interviews coworker and friend Ellen who works in a different sector for...
01:14:42
053 - Amarin Raises Guidance on Vascepa Label Expansion. ASH Updates Impress.
Amarin finally receives label expansion for Vascepa, which can now be marketed to patients with...
22:53
053 - Amarin Raises Guidance on Vascepa Label Expansion Approval. ASH Updates Impress.
Amarin finally receives label expansion for Vascepa, which can now be marketed to patients with...
22:53
052 - BATTLING for the Top Anti-VEGF Eye Therapy
Happy Thanksgiving! In this video, I talk about all things related to eye diseases caused by...
21:44
051 - Amarin Receives UNANIMOUS Recommendation from Advisory Committee
I'm back! Here are the companies I touch on in this episode (recorded on Nov 14, 2019):...
22:27
050 - Acasti Pharma's Novel Omega-3 Formulation Steps Up!
Hey everybody, we made it to #50! In this episode, I chat with Nathan Weinstein from Aegis...
20:24
049 - Is Odonate's Hype Overblown?
Today, I talk breast cancer and how Odonate's oral Taxane (Tesataxel) could garner the attention...
27:31
048 - Advisory Committee votes YES on Aimmune's Palforzia
In this video, I discuss the details of the advisory committee that recently occurred regarding...
24:53
047 - Sarepta Receives CRL for Golodirsen! IOVA impresses in solid tumors.
In this video, I talk about Sarepta and their issues regarding the CRL received for Golodirsen. I...
28:00
046 - FDA Announces Last Minute Advisory Committee For Amarin's Vascepa
Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA...
21:58
045 - Gilead PrEP Revenue in JEOPARDY!
Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a...
22:55
044 - Marker Therapeutics DISAPPOINTS in pancreatic cancer
Hi all, today I talk about the #MRKR interim update of their MultiTAA treatment in pancreatic...
25:03
043 - Sarepta keeps the gene therapy throne in DMD! ContraVir submits NASH IND!
Hey everybody, hope you're all doing well! In this video, I talk about Pfizer's DMD gene therapy...
24:31
042 - Biotech M&As accelerate. IMMU's ADC shakes up breast cancer!
Today, I cover the latest in biotech with a highlight on Immunomedics and their antibody-drug...
19:06
041 - Is REGENXBIO a buy after Zolgensma approval?
Today, I talk about REGENXBIO and their in-house gene therapy candidates. Their most important...
30:29
040 - Biogen faces another headwind with Zolgensma approval
Hi all, I'm back today talking about the approval of Avexis/Novartis' gene therapy for spinal...
34:00
039 - Will Marker Therapeutics Succeed in Pancreatic Cancer?
Hi everybody, in this episode I take a deeper dive into pancreatic cancer and how Marker...
21:06
038 - Democrats scare the healthcare sector plus Marker Therapeutics breakdown
Hey all, tonight I talk about the latest downswing in biotech/pharma and I breakdown Marker...
40:39
037 - Sangamo Bounces Back! Viking's Backup Drug
In this video, I go through Sangamo's updated data with their Hemophilia A and Beta-Thalassemia...
28:24
Premium
Plus